Type II and type III cryoglobulinemic vasculitis (CV) are characterized by a deranged immune function due to concomitant chronic infections or rheumatic disorders. Conversely, type I CV is caused by plasma cell dyscrasia. Bortezomib is a proteasome inhibitor that is largely employed as a first-line treatment for multiple myeloma. The use of bortezomib in cases of monoclonal gammopathy of undetermined significance (MGUS)-related refractory type I CV has been reported in only four patients. In the current report, we discuss the efficacy of bortezomib treatment in a patient with type I CV, with a focus on the suitability and early application of this drug.
Introduction
Type I cryoglobulinemic vasculitis (CV) is a rare variant of CV in which cryoglobulins are formed by aggregating monoclonal immunoglobulins due to the presence of monoclonal gammopathy of undetermined significance (MGUS), multiple myeloma (MM) or Waldenström's macroglobulinemia. Type I cryoglobulins share with type II and type III cryoglobulins the ability to precipitate at lower temperature and cause both small vessel damage and end-organ ischemia. Although classic neutrophil-mediated mechanisms induce vessel wall damage in patients with type I CV, physical causes of vessel occlusion, such as cryoglobulin precipitation in the microvasculature and hyperviscosity, predominate (1) . In contrast, type II and type III CV are characterized by the presence of prominent immune complex deposition, complement activation and neutrophil recruitment at sites of vessel damage against a background of intense systemic inflammation, primarily caused by chronic hepatitis C virus (HCV) infection or rheumatic diseases (1) . In the latter context, self-sustaining feedback loops between non-plasma cell B-lymphocytes and neutrophils as well as B-and Tlymphocytes (2, 3) ensure the maintenance of inflammation and vessel injury. Conversely, in the setting of type I CV, a neoplastic or pre-neoplastic deviation of the function of plasma cells constitute the core of the pathogenesis. In addition to the use of antiviral agents in cases of HCV-related CV, the treatment of CV is primarily based on the use of protocols adapted from ANCA-associated vasculitis (AAV), including corticosteroids and, in severe cases, cyclophosphamide and rituximab as the main therapeutic options (4) . The efficacy of rituximab in patients with type II and III CV is supported by the active role of this drug in silencing Bcell-mediated antigen presentation to T-cells and the maintenance of a proinflammatory cytokine milieu, and by its effects on antibody production (3). On the other hand, the efficacy of rituximab in cases of type I CV is controversial due to the putative lack of efficacy against plasma cells, that are all constitutively CD20-negative (1). Nonetheless, AAVderived therapeutic regimens are applied to treat type II, III as well as type I CV. In the case of type I CV, the reported response rate to first-and second-line immunosuppressive treatment is 35% and 51%, respectively (1). Bortezomib is a proteasome inhibitor with an average time to response of 40 days (5) that is largely employed as a first-line treatment for MM (6) and has been reported to be effective in patients with refractory MM-associated CV (1) . The use of bortezomib in cases of MGUS-related refractory type I CV has been reported in only four patients (7) (8) (9) , as well as one case of type II CV with concomitant MGUS (10) . All patients showed a good response. In this report, we discuss the efficacy of bortezomib in patients with type I CV, with a focus on its suitability and early application in the setting of this disease, by describing a case observed in our unit.
Case Report
A 51-year-old man was referred to our unit for unremitting burning pain in the lower limbs and progressive necrosis of the II-IV digits of the left foot. His past history was significant for seronegative spondyloarthritis (for which he received methotrexate, infliximab and adalimumab) and IgG kappa MGUS. He had subsequently developed a relapsing/ remitting purpuric rash on the lower limbs, which had progressed to a fixed non-purpuric vasculitic rash on the upper and lower limbs and digital ischemia of the left foot over the last year. In addition, distal axonal polyneuropathy with intense burning pain had emerged in the lower limbs. A skin biopsy revealed non-specific small vessel vasculitis. The patient had then been diagnosed with CV based on the detection of 6% cryocrit in the serum. At that time, both anti-HCV antibodies and rheumatoid factor were negative. He was then treated with high-dose steroids in association with cyclophosphamide, rituximab, intravenous immunoglobulins and multiple cycles of plasmapheresis, with a modest improvement.
On admission, the patient's heart rate was 90 bpm, his blood pressure was 150/100 and his oxygen saturation was 96% while breathing room air. He was febrile (temperature: 39 ) and complained of severe pain in the lower limbs. Advanced necrosis and signs of infection were evident in the II-IV digits of the left foot. In addition, both feet were cyanotic and cold, and diffuse cutaneous vasculitis was notable in the lower and upper limbs (Fig. 1) . Laboratory tests showed CRP elevation, with normal levels of C3 and C4 and IgG K monoclonal gammopathy at a value of 7.1 g/L (Table 1) . Type I cryoglobulins were detected at a high concentration (6% cryocrit). The patient initially underwent 10 days of broad-spectrum antimicrobial and antifungal therapy, with a partial benefit. However, his fever persisted (temperature: 38 ) in addition to elevation of inflammatory indices ( Table 1 ). The necrosis in the lower limbs also extended to both forefeet, and cyanosis was detected in both hands. Further findings of hypertension, an increased serum creatinine level, active urinary sediment and proteinuria of 1.54 g/24 hours were suggestive of acute glomerulonephritis. Given the lack of efficacy of the previous treatment, we decided to start the patient on off-label intravenous pulse dexamethasone and subcutaneous bortezomib, as previously described (9) . Specifically, the patient received dexamethasone at a dose of 40 mg on days 1-2, 4-5, 8-9 and11-12 every 21 days and bortezomib at a dose of 1.3 mg/m 2 on days 1, 4, 8 and 11 every 21 days. He also received prednisone at a dose of 1 mg/kg with progressive tapering, in the days in which dexamethasone was not administered. After two cycles of therapy, the serum creatinine, 24-hour proteinuria and systemic blood pressure values returned to the normal ranges, suggesting remission of CV-related nephritis. In addition, the cyanosis of the upper limbs and cutaneous rash dramatically improved, together with the disappearance of the fever, abatement of the cryocrit level and normalization of acutephase reactant levels. However, we were unable to reverse the necrosis in the forefeet, both of which were amputated. The neuropathic pain appeared to improve only transiently, and the dose of bortezomib was reduced to 1 mg/m 2 for the third cycle based on our suspicion of bortezomib-related neurotoxicity. However, after the fourth cycle of treatment, all of the patient's neurological symptoms resolved, and bortezomib was readministered at a full dose, with no subsequent effects on the neuropathic pain. An additional potential drug-related toxicity consisted of mild diarrhea, which resolved spontaneously.
Discussion
In this brief report, we described a case of MGUS-related refractory type I CV with cutaneous, nervous and renal involvement that required the use of high-dose corticosteroids and bortezomib. Type I CV vasculitis is a rare subset of CV in which skin involvement (with either palpable purpura or cutaneous vasculitis in addition to ulcers and soft tissue necrosis) is almost invariably present. Peripheral nerve involvement and nephritis are reported to affect roughly 1/3 of patients. Complement consumption is usually less frequent and less intense (1). In the largest series of type I CV published to date, only seven patients (all with MM) treated with bortezomib-based regimens (as first-to fourth-line treatment) were described; the authors reported an overall response rate of 86% (1). In addition, four cases of MGUSrelated type I CV treated with bortezomib have been previously published (Table 2 ) (7-9). As in the current case, the prevalent clinical phenotype was that of a middle-aged man with prominent skin involvement due to type I CV with evidence of IgG κ monoclonal gammopathy. Renal and nervous system involvement further complicated the disease course of our patient. All patients described in previous reports underwent treatment with multiple lines of chemotherapy before receiving bortezomib + dexamethasone, a therapeutic regimen adapted from those employed for MM. In one case, bortezomib and dexamethasone were administered against a background of systemic corticosteroid + azathioprine therapy (8) . We also decided to start the current patient on therapy with 1 mg/kg of prednisone, which was progressively tapered over one month. In this case, our choice was prompted by the aim of achieving a rapid and robust reduction of the signs of systemic inflammation. On the other hand, treatment with dexamethasone provided a specific plasma cell lysis effect as well as a protective effect against a subsequent cytokine storm.
All four patients reported in the literature showed a good clinical response after one to two cycles of bortezomib + dexamethasone treatment. Peripheral neuropathy was the only significant side effect, reported in one of the four cases. In line with previous reports and the expected time to response according to the literature (5), we observed a dramatic improvement in most of our patient's clinical and laboratory parameters, which returned to the normal ranges after two cycles. However, we failed to save the patient's forefeet, as the necrosis was too advanced at the time the treatment was initiated. The patient subsequently exhibited transient worsening of the peripheral neuropathy, which ultimately resolved despite restoring the full-dose bortezomib treatment. A previous history of peripheral neuropathy is the main risk factor for bortezomib-related neurotoxicity (11) , which cannot be excluded in the case. However, since the worsening occurred during steroid tapering, a steroid withdrawal effect may also be hypothesized.
In conclusion, we confirmed the reported efficacy of the bortezomib + dexamethasone regimen as a treatment for refractory MGUS-associated type I CV. However, this case also demonstrates that the delayed response evoked by bortezomib therapy may constitute a limit, especially in critical settings requiring a quick response when other therapies have failed. We therefore suggest that combination therapy consisting of high-dose corticosteroids and bortezomib +/-plasmapheresis can be suitably employed at disease onset in patients with severe type I CV (Fig. 2) . This strategy has the potential to directly impact the pathogenic core of the disease, i.e., plasma cell dyscrasia, in contrast to conventional treatments, such as cyclophosphamide and rituximab, which actively target proliferating lymphocytes, i.e., the pathogenic core of type II and III CV. Larger controlled studies are required to test this hypothesis, although the low incidence of the disease could make this task very challenging.
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